

BOX AF

350.00 - 116 - 9152



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

15/Ext²
AMD7C
1/23/92

In re PATENT Application of
Helmut HETTCHE

Serial No. 07/551,664

Group Art Unit: 152

Filed: July 12, 1990

Examiner: L. Piccone

For: AZELASTINE-CONTAINING MEDICAME
NTS

January 15, 1992

RECEIVED

JAN 22 1992

GROUP 150

* * * * *

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Dear Sir:

Responsive to the Office Action of September 12, 1991,
please amend the above-identified application as follows:

IN THE CLAIMS:

Cancel claims 13-17.

REMARKS

The applicant respectfully requests reconsideration.

The claims stand rejected as obvious from the disclosure of the cited Vogelsang, et al. patent in view of the art admitted in the specification. The claims relate to administration of azelastine directly into nasal and eye tissues.

It is not clear what aspects of the art admitted in the specification is the basis of the examiner's reference, but the introductory passage on page 1 simply mentions to the fact that azelastine has anti-allergic and anti-histamine properties. However, this information does not imply a mode of administration, although, as shown below, the customary mode of administration for such medications is systemic (e.g., oral or injection). Further, as the cited Vogelsang patent refers to the fact that its compounds are used for